Launched new skin repair development program targeting $19B in unmet medical needs Successfully demonstrated protection from joint degeneration and osteoarthritis post meniscal repair surgery in ORTHO-R large animal study Concluded enrollment of Phase I/II clinical trial for rotator cuff tear repair Secured 4-yr off balance sheet $3.5 million grant to advance R&D initiatives Now focused on activities leading to faster commercial status and evaluating opportunities for fast-track regulatory programs Reduced operating losses by 79% and 75% during Q4-24 and FY-24 respectively compared to prior year     MONTREAL, May 28, 2024 /CNW/ - ChitogenX Inc., (CSE:CHGX) (OTCQB:CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today reported its financial results and highlights for the fourth quarter and fiscal year 2024 ended on January 31, 2024. ''Regenerative medicine, one of the fastest expanding and most exciting field in modern medicine is faced with limitations, namely the absence of a solution allowing for administered substances to remain on the site of delivery long enough to have its desired and designed effects. This is where ChitogenX's solution comes into play. Our chitosan-based biopolymer is a safe and reliable delivery mechanism to aid in repairing tissues and organs. Its unique properties offer the unique benefit of significantly increasing the in-situ residency time of cells, pharmaceutical, or biologic implants so that they may deliver their regenerative effects", said Pierre Laurin, President, and CEO. "After having successfully generated proof of concept data, we can now focus on activities that will lead to faster commercial status. As such, we are evaluating opportunities for fast-track regulatory programs with potential 510(k) pre-market submissions in the US and commercial readiness in other jurisdictions''.  Commenting on the fourth quarter and fiscal 2024 results, Luc Mainville, ChitogenX' Senior Vice-President, ...